ArticleWomen's health reports (New Rochelle, N.Y.)2025
Characterization and Treatment Patterns of Peri/Menopausal and Postmenopausal Women with and Without Vasomotor Symptoms in a Retrospective Database Study.
Article in Women's health reports (New Rochelle, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Vasomotor symptoms (VMS) are the most commonly reported menopausal symptoms and vary across race and ethnicity, with higher prevalence and duration among Black and Hispanic women. This study describes demographics/clinical characteristics and treatment patterns of peri/menopausal and postmenopausal women with symptomatic menopause/VMS and asymptomatic menopause in a commercial claims population. Methods: Data from Optum's deidentified Clinformatics Data Mart Database were obtained for peri/menopausal (aged 40-54 years) and postmenopausal (aged 55-64 years) women. VMS is not available directly in claims data and was proxied using symptomatic menopausal ICD-9/10 codes. In Phase 1, prevalence of symptomatic and asymptomatic peri/menopause (defined by ICD-9/10 codes) and baseline demographics/clinical characteristics were obtained. Phase 2 included baseline demographics/clinical characteristics, symptomatic menopause/VMS incidence rates, and treatment patterns. Results: Phase 1 included 1,987,355 ICD-9/10 codes for symptomatic or asymptomatic menopause. Peri/menopausal women had lower symptomatic menopause/VMS prevalence compared to postmenopausal women (6.5% vs. 4.9%). Symptomatic menopause/VMS prevalence was 5.7% and highest in White (6.3%) and lowest in Asian (3.4%) women.Phase 2 included 203,546 (53.3%) peri/menopausal and 178,658 (46.7%) postmenopausal women. Symptomatic menopause/VMS incidence was 1.2%; only 52.9% were treated. Lower incidence and treatment rates were seen among Asian (0.46%; 33.2%), Hispanic (0.43%; 46.7%), and Black (0.41%; 47.1%) women compared to White (0.59%; 55.5%) women. Conclusions: This study adds to the literature by characterizing women with symptomatic menopause/VMS across the menopausal spectrum and shows that caution is needed when interpreting real-world claims data due to inherent claims database limitations. As there are no specific ICD codes for VMS, difficulties exist in utilization of claims data to accurately capture VMS characteristics and treatment patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.